Metropolis Healthcare Ltd
NSE:METROPOLIS
Metropolis Healthcare Ltd
Metropolis Healthcare Ltd., a pioneer in the diagnostics industry, embarked on its journey in 1980 under the visionary leadership of Dr. Sushil Kanubhai Shah. This Mumbai-based company quickly established itself as a trusted name, offering a comprehensive range of diagnostic services, including pathology tests, radiology, and wellness solutions. The heart of its operations lies in its expansive network of laboratories and collection centers strategically distributed across India and several international locations. By leveraging state-of-the-art technology and maintaining rigorous quality standards, Metropolis has positioned itself as a forerunner in providing precise and reliable medical test results. This was especially crucial as the demand for accurate healthcare diagnostics surged, driven by an increasingly health-conscious population.
Metropolis generates its revenue primarily through fees charged for its broad spectrum of diagnostic tests that cater to a variety of health needs, from routine screenings to specialized, high-complexity tests. Its business model capitalizes on partnerships with healthcare providers, hospitals, and corporations, offering customized health packages and diagnostic solutions that ensure a steady flow of clientele. By integrating advanced testing technologies and continuously expanding its service portfolio, the company taps into diverse revenue streams, which include corporate wellness programs and home health services. This diversified approach not only enhances its financial stability but also solidifies its reputation as a go-to healthcare partner for individuals, corporate clients, and healthcare institutions alike.
Metropolis Healthcare Ltd., a pioneer in the diagnostics industry, embarked on its journey in 1980 under the visionary leadership of Dr. Sushil Kanubhai Shah. This Mumbai-based company quickly established itself as a trusted name, offering a comprehensive range of diagnostic services, including pathology tests, radiology, and wellness solutions. The heart of its operations lies in its expansive network of laboratories and collection centers strategically distributed across India and several international locations. By leveraging state-of-the-art technology and maintaining rigorous quality standards, Metropolis has positioned itself as a forerunner in providing precise and reliable medical test results. This was especially crucial as the demand for accurate healthcare diagnostics surged, driven by an increasingly health-conscious population.
Metropolis generates its revenue primarily through fees charged for its broad spectrum of diagnostic tests that cater to a variety of health needs, from routine screenings to specialized, high-complexity tests. Its business model capitalizes on partnerships with healthcare providers, hospitals, and corporations, offering customized health packages and diagnostic solutions that ensure a steady flow of clientele. By integrating advanced testing technologies and continuously expanding its service portfolio, the company taps into diverse revenue streams, which include corporate wellness programs and home health services. This diversified approach not only enhances its financial stability but also solidifies its reputation as a go-to healthcare partner for individuals, corporate clients, and healthcare institutions alike.
Strong Revenue Growth: Group revenue grew 26% year-on-year in Q3, with organic revenue up 15% year-on-year, supported by broad-based performance across segments and geographies.
Margin Expansion: Organic EBITDA margin improved by 280 basis points to 25%, driven by cost efficiencies and productivity initiatives, despite a one-time labor code impact.
Guidance Maintained: Management reaffirmed organic revenue growth guidance of 12% to 13% and expects to hit the higher end of this range, with further margin expansion anticipated.
Genomics & Specialty Growth: The company launched its Centre of Genomics, integrated Core Diagnostics, and saw rapid uptake in genomics and specialty tests, targeting high-value, non-commoditized diagnostics.
Network Expansion: Added 110 new centers in the quarter (over 300 in 9 months), now present in 750 towns, focusing on deeper penetration via franchise channels.
Bonus Share Issue: Board approved a 3:1 bonus share issue, reflecting confidence in long-term growth and strong financial position.
North India Momentum: Revenue contribution from North India rose from 9% to 17% post-acquisitions, with the region outpacing group growth.
